Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 3/20 | 0.44 |
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | CNR2 | P34972 | 5/20 | 0.39 |
| ▸ | HRH2 | P25021 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601803 | 0.91 | HRH2 (0.44) | ICMTRENCNR1CNR2HRH2 | |
| SCHEMBL4602810 | 0.89 | ICMT (0.44) | ICMTRENCNR1CNR2HTR6 | |
| SCHEMBL91360 | 0.85 | REN (0.44) | RENCNR1CNR2PDE4APDE4B | |
| SCHEMBL4602440 | 0.84 | ICMT (0.43) | ICMTCNR1CNR2HRH2HTR6 | |
| SCHEMBL91271 | 0.83 | ICMT (0.54) | ICMTRENCNR1CNR2HRH2 | |
| SCHEMBL13962817 | 0.83 | REN (0.42) | RENCNR1CNR2PDE4APDE4B | |
| SCHEMBL13962829 | 0.83 | REN (0.42) | RENCNR1CNR2PDE4APDE4B | |
| SCHEMBL1050732 | 0.83 | REN (0.42) | RENCNR1CNR2HTR6PDE4A | |
| SCHEMBL14577787 | 0.82 | ICMT (0.62) | ICMTCNR1CNR2PDE4APDE4B | |
| SCHEMBL78476 | 0.82 | ICMT (0.42) | ICMTCNR1CNR2HRH2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | claimed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | claimed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | claimed |
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | disclosed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242662-A1 | Organic Compounds | REN, ACE, ECE1 | ICMT 2436/4885REN 1/4885CNR1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.